UBS Group
RGC icon

UBS Group’s Regencell Bioscience RGC Stock Holding History

UBS Group’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$607K Buy
23,885
+5,682
+31% +$161K ﹤0.01% 5942
2025
Q4 		$382K Buy
18,203
+17,823
+4,690% +$290K ﹤0.01% 6238
2025
Q3 		$5.87K Sell
380
-37,147
-99% -$533K ﹤0.01% 8822
2025
Q2 		$639K Buy
+37,527
New +$458K ﹤0.01% 5811
2025
Q1 		– Sell
-1,110,284
Closed -$144K – 10640
2024
Q4 		$144K Buy
1,110,284
+430,996
+63% +$64.8K ﹤0.01% 6658
2024
Q3 		$99.1K Buy
679,288
+667,432
+5,629% +$127K ﹤0.01% 6380
2024
Q2 		$1.05K Sell
11,856
-41,344
-78% -$5.12K ﹤0.01% 8675
2024
Q1 		$6.3K Sell
53,200
-556,814
-91% -$96.2K ﹤0.01% 7471
2023
Q4 		$169K Buy
+610,014
New +$224K ﹤0.01% 5884
2023
Q2 		– Sell
-38
Closed -$26 – 9517
2023
Q1 		$26 Sell
38
-25,384
-100% -$18.7K ﹤0.01% 9400
2022
Q4 		$18.2K Buy
25,422
+4,598
+22% +$3.52K ﹤0.01% 7756
2022
Q3 		$17K Sell
20,824
-6,650
-24% -$5.82K ﹤0.01% 7613
2022
Q2 		$25K Buy
27,474
+18,202
+196% +$13.7K ﹤0.01% 6611
2022
Q1 		$5K Buy
9,272
+1,976
+27% +$1.69K ﹤0.01% 9157
2021
Q4 		$6K Buy
+7,296
New +$4.42K ﹤0.01% 9289

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
VA
Vident Advisory Alpharetta, Georgia $11.7B AUM 37.32% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group's RGC Position: Q1 2026 in Review

UBS Group increased its Regencell Bioscience (RGC) stake by 31% in Q1 2026, buying an estimated $161K and bringing the position to 23,885 shares worth $607K. The position accounts for ﹤0.01% of the portfolio, ranked #5942.

UBS Group first reported a position in RGC in Q4 2021 and has held it in 15 quarters since. The position peaked at $639K in Q2 2025. 31 funds tracked by Wall St. Rank hold RGC as of Q1 2026.

  • UBS Group held 23,885 shares of Regencell Bioscience worth $607K as of Q1 2026.
  • UBS Group bought 5,682 Regencell Bioscience shares in Q1 2026, an estimated $161K.
  • Regencell Bioscience made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5942 holding.
  • UBS Group first reported a position in Regencell Bioscience in Q4 2021 and has held it in 15 quarters since.
  • UBS Group's Regencell Bioscience position peaked at $639K in Q2 2025.
  • 31 funds tracked by Wall St. Rank held Regencell Bioscience as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.